Life Sciences

  • February 07, 2025

    Trump Isn't Obeying Order To Unfreeze Funds, States Say

    The Trump administration is not complying with a temporary restraining order barring a freeze on funding for federal grant and aid programs, a coalition of states told a Rhode Island federal judge Friday, asking the court to enforce its order and to enter a stiffer injunction blocking the funding freeze.

  • February 07, 2025

    NC Judge Knocked By Fed. Circ. For Rushing Patent Trial

    A Federal Circuit panel on Friday stripped a patent case over respiratory treatment devices away from a North Carolina federal judge, with the appeals court reversing a noninfringement verdict that came out of a jury trial he oversaw and finding that it was at least the second time the judge "did not intend to manage a fair trial."

  • February 07, 2025

    NJ Statehouse Catch-Up: Offshore Wind, AI, Neurodiversity

    The retraction of New Jersey's fourth offshore wind solicitation came alongside a wave of legislative and regulatory activity that also proposed workplace rules to bolster inclusivity and a new compensation path for assault victims

  • February 07, 2025

    70 Depo-Provera Suits Joined In Florida's Northern District

    The U.S. Judicial Panel on Multidistrict Litigation on Friday consolidated more than 70 consumer lawsuits claiming that Pfizer Inc. failed to adequately warn patients and doctors about the risk of brain tumors associated with the hormonal contraceptive drug Depo-Provera in the Northern District of Florida.

  • February 07, 2025

    SPAC Market Hums Again Following Multiyear Downturn

    Special purpose acquisition companies are once again asserting their presence in the capital markets and M&A landscape, forming new vehicles at the highest pace in three years — albeit in leaner form than in the last cycle, when many deals ended in busts.

  • February 07, 2025

    Fed. Circ. Backs Ventria Cell Culture Patent Win At ITC

    In a precedential decision, the Federal Circuit said Friday that the U.S. International Trade Commission's domestic industry requirements have no "threshold dollar value" and that "small market segments" operated by biotech developer Ventria Bioscience can qualify, upholding the ITC's finding that a Chinese vaccine developer infringed Ventria's cell culture patent.

  • February 07, 2025

    Fed. Circ. Considers Some Testing For Avadel Sleep Drug

    Judges on the Federal Circuit seemed open to modifying a district court's injunction barring specialty drugmaker Avadel Pharmaceuticals from marketing its on-market narcolepsy drug for use in treating another sleep disorder Friday.

  • February 07, 2025

    Pa. Medical Pot Co. Beats Consultant's IP Breach Claims

    A Pennsylvania federal judge has thrown out a lawsuit filed by a consultant claiming that his methods for growing plant tissue samples was stolen by a medical cannabis company he worked with, ruling that the consultant's system was not a protected trade secret.

  • February 07, 2025

    Del.'s Quiet Ambition To Tweak Chancery, Stem Feared DExit

    Anxious over claims that stockholder-tilted decisions by Delaware's Court of Chancery will trigger more companies to follow Tesla, SpaceX, Meta and Dropbox to other states, Delaware policymakers are taking a hard look at the venerable business court's processes, hoping to slow a feared rush to DExit.

  • February 07, 2025

    Trump Drops High Court Opposition To Transgender Care Ban

    The federal government on Friday changed course in a U.S. Supreme Court case challenging a Tennessee ban on transgender care for minors, telling the court that the Trump administration's position is that the statute does not deny equal protection on the basis of sex.

  • February 07, 2025

    Life Sciences Group Of The Year: Cooley

    Cooley LLP advised radiopharmaceutical therapeutics company RayzeBio on its $4.1 billion post-IPO sale to Bristol Myers Squibb and helped biopharmaceutical company Liquidia nab significant victories in a patent dispute with United Therapeutics, earning the firm a place among the 2024 Law360 Life Sciences Groups of the Year.

  • February 07, 2025

    Taxation With Representation: Kirkland, Latham, Skadden

    In this week's Taxation With Representation, Triumph Group goes private via Berkshire Partners and Warburg Pincus affiliates, alternative asset manager TPG buys Altus Power, Globus Medical buys Nevro Corp., and Honeywell separates its automation and aerospace technology businesses, resulting in the formation of three distinct companies.

  • February 07, 2025

    3 Firms Guide Bain On $3.4B Japanese Pharma Co. Buy

    Bain Capital said Friday it has agreed to acquire Mitsubishi Tanabe Pharma Corp. from Mitsubishi Chemical Group Corp., in a carveout transaction that values the target at approximately JPY 510 billion, or about $3.36 billion.

  • February 07, 2025

    UK Litigation Roundup: Here's What You Missed In London

    This past week in London has seen Investec Bank PLC sue two diamond tycoons, London florist Nikki Tibbles file a claim against an "imitator company," a direct descendant of the Cartier family launch a claim, and a Coronation Street actor hit footballer Joe Bunney with a defamation claim. Here, Law360 looks at these and other new claims in the U.K.

  • February 06, 2025

    Doctors Org. Wants Health Agency Website Info Restored

    An advocacy organization representing physicians asked a Washington, D.C., federal judge Thursday to require federal agencies to restore public-health related web pages and data that were taken down after the Office of Personnel Management directed the agencies to root out references to "gender ideology" on their websites.

  • February 06, 2025

    Tom's 'Natural' Kids Toothpaste Has Lead, Arsenic, Dad Says

    Tom's of Maine and its parent company Colgate-Palmolive have "egregiously" failed to disclose that its "Silly Strawberry" children's toothpaste has dangerous levels of lead and arsenic, a New York dad alleged in a proposed false advertising class action filed Thursday in New York federal court.

  • February 06, 2025

    Sterilization Plant's 'Royal' Mistake Leaked Pollution, Jury Told

    A former head of Terumo BCT Inc.'s Colorado medical sterilization facility testified Thursday that after a 2008 incident that he called a "royal fuck up" resulted in the release of a toxic chemical inside the plant, Terumo aired out the building and allowed the emissions to go outside.

  • February 06, 2025

    Goodwin, Ropes Lead Cystic Fibrosis Co.'s Upsized $191M IPO

    Cystic fibrosis-focused drug developer Sionna Therapeutics Inc. on Thursday priced an upsized $191 million initial public offering at the top of its range, represented by Goodwin Procter LLP and underwriters counsel Ropes & Gray LLP.

  • February 06, 2025

    Buyers Want Kratom Cos. Addiction Suit To Go On

    Two California kratom manufacturers shouldn't be allowed to escape a lawsuit claiming they failed to warn about the "highly addictive" nature of their products, a proposed class of consumers argued, pointing to a podcast where a company executive suggested their products were more potent than morphine.

  • February 06, 2025

    CooperSurgical Hit With IVF Embryo Loss Class Claims

    A proposed class has sued CooperSurgical Inc. over embryos lost to its defective culture medium for in vitro fertilization, in the latest complaint in a series of individual lawsuits brought against the company after its 2023 recall of the product.

  • February 06, 2025

    Drug Cos. Urge Full Fed. Circ. To Hear Teva Orange Book Row

    The branded pharmaceutical industry is lining up behind a legal effort from Israeli drugmaker Teva that wants the full Federal Circuit to hear a dispute over delisting patents from the U.S. Food and Drug Administration's Orange Book.

  • February 06, 2025

    UnitedHealth Drops Bid To Toss Home Health Deal Challenge

    UnitedHealth Group and home health and hospice giant Amedisys Inc. dropped their bid to toss a case challenging their $3.3 billion merger after enforcers detailed the home health and hospice markets they allege will be hurt by the deal.

  • February 06, 2025

    EIP Grows US Team With 2 Pranger Law Attys

    Global intellectual property firm EIP said Wednesday it has hired two attorneys from Pranger Law PC, including the head of its patent prosecution team.

  • February 06, 2025

    GSK's Zantac Woes Gave Investors Heartburn, Suit Says

    The maker of heartburn and acid reflux relief tablet Zantac has been hit with a shareholder suit in Pennsylvania federal court alleging that the company suffered stock price losses after it was revealed that for nearly 40 years the company knew that Zantac contained high levels of a cancer-causing compound.

  • February 06, 2025

    Globus Medical Buys Device-Maker Nevro In $250M Deal

    Musculoskeletal solutions company Globus Medical, advised by Wyrick Robbins Yates & Ponton LLP, on Thursday announced plans to buy Latham & Watkins LLP-led medical device company Nevro Corp. in an all-cash deal with an equity value of roughly $250 million.

Expert Analysis

  • Will 4th Time Be A Charm For NY's 21st Century Antitrust Act?

    Author Photo

    New York's recently introduced 21st Century Antitrust Act would change the landscape of antitrust enforcement in the state and probably result in a sharp increase in claims — but first, the bill needs to gain traction after three aborted attempts, says Tyler Ross at Shinder Cantor.

  • Perspectives

    Accountant-Owned Law Firms Could Blur Ethical Lines

    Author Photo

    KPMG’s recent application to open a legal practice in Arizona represents the first overture by an accounting firm to take advantage of the state’s relaxed law firm ownership rules, but enforcing and supervising the practice of law by nonattorneys could prove particularly challenging, says Seth Laver at Goldberg Segalla.

  • The Post-Macquarie Securities Fraud-By-Omission Landscape

    Author Photo

    While the U.S. Supreme Court's 2024 opinion in Macquarie v. Moab distinguished inactionable "pure omissions" from actionable "half-truths," the line between the two concepts in practice is still unclear, presenting challenges for lower courts parsing statements that often fall within the gray area of "misleading by omission," say attorneys at Katten.

  • AI Will Soon Transform The E-Discovery Industrial Complex

    Author Photo

    Todd Itami at Covington discusses how generative artificial intelligence will reshape the current e-discovery paradigm, replacing the blunt instrument of data handling with a laser scalpel of fully integrated enterprise solutions — after first making e-discovery processes technically and legally harder.

  • IP, Licensing, M&A Trends To Watch In Life Sciences This Year

    Author Photo

    2025 promises to continue an exciting trajectory for the life sciences industry, with major trends ranging from global harmonization of intellectual property to cross-border licensing activity and an increase of nontraditional financial participants in the mergers and acquisition space, say attorneys at Morgan Lewis.

  • When Innovation Overwhelms The Rule Of Law

    Author Photo

    In an era where technology is rapidly evolving and artificial intelligence is seemingly everywhere, it’s worth asking if the law — both substantive precedent and procedural rules — can keep up with the light speed of innovation, says Reuben Guttman at Guttman Buschner.

  • Anticipating Direction Of Cosmetics Regulation Under Trump

    Author Photo

    It is unclear how cosmetics regulation reform from the last few years will fare under President Donald Trump, but the new administration's emphasis on deregulation and Robert F. Kennedy Jr.'s views on product safety provide some insight, say attorneys at Crowell & Moring.

  • Drug Pricing Policy Trends To Expect In 2025 And Beyond

    Author Photo

    Though 2025 may bring more of the same in the realm of drug pricing policy, business as usual entails a sustained, high level of legal and policy developments across at least six major areas, say attorneys at Ropes & Gray.

  • Imagine The Possibilities Of Openly Autistic Lawyering

    Author Photo

    Andi Mazingo at Lumen Law, who was diagnosed with autism about midway through her career, discusses how the legal profession can create inclusive workplaces that empower openly autistic lawyers and enhance innovation, and how neurodivergent attorneys can navigate the challenges and opportunities that come with disclosing one’s diagnosis.

  • Top 10 Healthcare And Life Sciences Issues To Watch In 2025

    Author Photo

    Under the new Trump administration, this coming year may benefit some healthcare and life sciences stakeholders, while creating new challenges for others amid an increasingly complex regulatory environment, say attorneys at Debevoise.

  • Parsing 3rd Circ. Ruling On Cannabis, Employee Private Suits

    Author Photo

    The Third Circuit recently upheld a decision that individuals don't have a private right of action for alleged violations of New Jersey's Cannabis Regulatory, Enforcement Assistance and Marketplace Modernization Act, but employers should stay informed as the court encouraged the state Legislature to amend the law, say attorneys at Mandelbaum Barrett.

  • 4 Keys To Litigating In An Active Regulatory Environment

    Author Photo

    For companies facing litigation influenced by government regulatory action — a recent trend that a politically charged atmosphere will exacerbate — there are a few principles that can help to align litigation strategy with broader public positioning in the regulatory and oversight context, say attorneys at Jenner & Block.

  • Kiromic SEC Order Shows Importance Of Self-Reporting

    Author Photo

    The U.S. Securities and Exchange Commission's recently filed settled charges against Kiromic BioPharma illustrate the critical intersection between U.S. Food and Drug Administration regulatory processes and investor disclosures under the securities laws, and showcase how responding promptly to internal whistleblower reports may reap benefits, say attorneys at Arnold & Porter.

  • Series

    Documentary Filmmaking Makes Me A Better Lawyer

    Author Photo

    Becoming a documentary filmmaker has allowed me to merge my legal expertise with my passion for storytelling, and has helped me to hone negotiation, critical thinking and problem-solving skills that are important to both endeavors, says Robert Darwell at Sheppard Mullin.

  • Litigation Funding Disclosure Debate: Strategy Considerations

    Author Photo

    In the ongoing debate over whether courts should require disclosure of litigation funding, funders and plaintiffs tend to argue against such mandates, but voluntarily disclosing limited details about a funding arrangement can actually confer certain benefits to plaintiffs in some scenarios, say Andrew Stulce and Marc Cavan at Longford Capital.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!